首页> The journal of pathology. Clinical research> Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors.

Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors.

导出 LinkOut

翻译打印收藏纠错

第一作者： Michael,Menzel

第一单位： Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.

作者： Michael,Menzel ^[1] ; Martina,Kirchner ^[1] ; Klaus,Kluck ^[1] ; Markus,Ball ^[1] ; Susanne,Beck ^[1] ; Michael,Allgäuer ^[1] ; Christin,Assmann ^[2] ; Johannes,Schnorbach ^[2] ; Anna-Lena,Volckmar ^[1] ; Timothy Kwang Yong,Tay ^[3] ; Hannah,Goldschmid ^[1] ; Daniel Sw,Tan ^[4] ; Michael,Thomas ^[2] ; Daniel,Kazdal ^[5] ; Jan,Budczies ^[1] ; Albrecht,Stenzinger ^[5] ; Petros,Christopoulos ^[2]

作者单位： Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany. ^[1] Translational Lung Research Center (TLRC) Heidelberg, Member of the German Center for Lung Research (DZL), Heidelberg, Germany.;Department of Thoracic Oncology, Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, Germany. ^[2] Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.;Department of Anatomical Pathology, Singapore General Hospital, Singapore. ^[3] Department of Clinical Trials and Epidemiological Sciences, National Cancer Centre, Singapore. ^[4] Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.;Translational Lung Research Center (TLRC) Heidelberg, Member of the German Center for Lung Research (DZL), Heidelberg, Germany. ^[5]

关键词 T790M mutation epidermal growth factor receptor (EGFR)non-small cell lung cancer (NSCLC)tumor heterogeneity tyrosine kinase inhibitor whole exome sequencing (WES)